公开(公告)号：US20190275091A1

公开(公告)日：2019-09-12

申请号：US16346576

申请日：2017-11-01

Applicant: OSAKA UNIVERSITY ,  GENOMIDEA INC.

Inventor： Yasufumi KANEDA ,  Kazuma SAKURA ,  Tomoyuki NISHIKAWA ,  Masanori FUKUSHIMA ,  Toshihiro NAKAJIMA

IPC: A61K35/76 ,  A61P35/00 ,  C12N7/00 ,  A61K39/395

Abstract: The present invention provides an anticancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) an inhibitor of an immune checkpoint protein.

公开(公告)号：US20180243355A1

公开(公告)日：2018-08-30

申请号：US15754687

申请日：2016-08-23

Applicant: OSAKA UNIVERSITY ,  Genomldea Inc.

Inventor： Yasufumi KANEDA ,  Toshihiro NAKAJIMA

IPC: A61K35/76 ,  A61P35/00 ,  C12N7/00 ,  A61K31/713 ,  A61K38/19

CPC classification number: A61K35/76 ,  A61K31/7088 ,  A61K31/713 ,  A61K31/739 ,  A61K38/19 ,  A61K38/195 ,  A61K45/00 ,  A61K48/00 ,  A61P35/00 ,  C12N7/00 ,  C12N2760/18833 ,  C12N2760/18871

Abstract: The present invention provides, as a new anti-cancer agent obtained by combining HVJ-E and a molecule synergistically acting therewith, an anti-cancer agent containing the following (1) and (2): (1) HVJ-E (hemagglutinating virus of Japan envelope), (2) CXCL2, a nucleic acid comprising a base sequence encoding CXCL2 or a CXCL2 expression inducing agent.